-transparent.png){kind=logo}
44% of 63 British patients with either haemophilia A or B were HTLV-III antibody positive (HTLV-VIII+). HTLV-III+ was more frequent in high factor VIII concentrate users and 75% of severely affected haemophilia A patients were HTLV-III+. All eight patients who were exposed to factor IX concentrate were HTLV-III-. 17 haemophilia A patients who received only British made factor VIII concentrate (average 12,000 units/year) were HTLV-III-. Two of 63 patients had evidence of a pre-AIDS type symptom complex and both were HTLV-III+. Information from a cohort of 21 Liverpool haemophiliacs suggests that HTLV-III was first introduced into this country in 1981. OKT4/T8 ratios were abnormal in 52% of 21 patients studied but this finding was not confined to either HTLV-III+ or HTLV-III- individuals. The spouses of 14 HTLV-III+ haemophiliacs were all HTLV-III-.
B A McVerry, and
S J Machin, and
M J Galloway, and
K McCarthy, and
P Evans, and
R M Barnes, and
G C Turner, and
R Cheingsong-Popov, and
R S Tedder, and
M Winter
October 1985,
British medical journal (Clinical research ed.),
B A McVerry, and
S J Machin, and
M J Galloway, and
K McCarthy, and
P Evans, and
R M Barnes, and
G C Turner, and
R Cheingsong-Popov, and
R S Tedder, and
M Winter
March 1985,
Lancet (London, England),
B A McVerry, and
S J Machin, and
M J Galloway, and
K McCarthy, and
P Evans, and
R M Barnes, and
G C Turner, and
R Cheingsong-Popov, and
R S Tedder, and
M Winter
March 1984,
JAMA,
B A McVerry, and
S J Machin, and
M J Galloway, and
K McCarthy, and
P Evans, and
R M Barnes, and
G C Turner, and
R Cheingsong-Popov, and
R S Tedder, and
M Winter
July 1986,
British medical journal (Clinical research ed.),
B A McVerry, and
S J Machin, and
M J Galloway, and
K McCarthy, and
P Evans, and
R M Barnes, and
G C Turner, and
R Cheingsong-Popov, and
R S Tedder, and
M Winter
December 1984,
Lancet (London, England),
B A McVerry, and
S J Machin, and
M J Galloway, and
K McCarthy, and
P Evans, and
R M Barnes, and
G C Turner, and
R Cheingsong-Popov, and
R S Tedder, and
M Winter
August 1985,
Lancet (London, England),
B A McVerry, and
S J Machin, and
M J Galloway, and
K McCarthy, and
P Evans, and
R M Barnes, and
G C Turner, and
R Cheingsong-Popov, and
R S Tedder, and
M Winter
January 1999,
Intensive care medicine,
B A McVerry, and
S J Machin, and
M J Galloway, and
K McCarthy, and
P Evans, and
R M Barnes, and
G C Turner, and
R Cheingsong-Popov, and
R S Tedder, and
M Winter
January 1987,
Immunology letters,
B A McVerry, and
S J Machin, and
M J Galloway, and
K McCarthy, and
P Evans, and
R M Barnes, and
G C Turner, and
R Cheingsong-Popov, and
R S Tedder, and
M Winter
February 1986,
Clinical and experimental immunology,
B A McVerry, and
S J Machin, and
M J Galloway, and
K McCarthy, and
P Evans, and
R M Barnes, and
G C Turner, and
R Cheingsong-Popov, and
R S Tedder, and
M Winter
September 1985,
Blood,
